ArticleFrontiers in oncology2025
Rare case report: sclerosing epithelioid fibrosarcoma with FUS-CREB3L1 gene fusion.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Primary sclerosing epithelioid fibrosarcoma of the iliac fossa: a case report.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sclerosing epithelioid fibrosarcoma (SEF) is a rare soft tissue malignancy frequently misdiagnosed due to its overlapping immunohistochemical and molecular features with low-grade fibromyxoid sarcoma (LGFMS). We present the case of a 60-year-old male who initially presented with a mass in the left thigh four years ago, which significantly increased in size over the past year. MRI of the femur revealed a large, well-circumscribed mass in the mid and lower left thigh. Surgical excision of the tumor and associated thrombus in the ipsilateral blood vessel was performed. Histomorphological analysis confirmed a pure SEF with no myxoid stroma, aiding in its differentiation from LGFMS. Immunohistochemical staining revealed diffuse and strong MUC4 positivity, while next-generation sequencing (NGS) demonstrated molecular characteristics consistent with LGFMS, specifically FUS-CREB3L1 gene fusion. This case underscores the asynchrony between the pathological morphology and molecular features of soft tissue tumors during their development and differentiation. Although histologically low-grade, SEF typically exhibits a high rate of local recurrence and distant metastasis. We diagnosed this case as SEF and recommended an aggressive clinical treatment regimen. This report aims to raise awareness of the diagnostic challenges associated with SEF and LGFMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.